<?xml version="1.0" encoding="UTF-8"?>
<collection>
<dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:invenio="http://invenio-software.org/elements/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:identifier>doi:10.3390/jcm11051258</dc:identifier><dc:language>eng</dc:language><dc:creator>Latorre, E.</dc:creator><dc:creator>Mesonero, J. E.</dc:creator><dc:title>Special Issue “Clinical Advances in Chronic Intestinal Diseases Treatment”</dc:title><dc:identifier>ART-2022-128158</dc:identifier><dc:description>During the last decades, the management of patients with chronic intestinal diseases has experienced remarkable progress from both diagnostic and therapeutic point of view. Irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) are the best known and with the highest incidence and prevalence around the world among chronic intestinal pathologies. Both chronic conditions display a significant overlap in terms of symptoms, pathophysiology, and treatments. However, these chronic intestinal diseases are poorly characterized and the understanding about is limited. New clinical approaches with novel mechanisms of action may offer more efficient options for treatment of chronic intestinal diseases, especially in those patients who are not optimally characterized or controlled.</dc:description><dc:date>2022</dc:date><dc:source>http://zaguan.unizar.es/record/130081</dc:source><dc:doi>10.3390/jcm11051258</dc:doi><dc:identifier>http://zaguan.unizar.es/record/130081</dc:identifier><dc:identifier>oai:zaguan.unizar.es:130081</dc:identifier><dc:identifier.citation>Journal of Clinical Medicine 11, 5 (2022), 1258 [3 pp]</dc:identifier.citation><dc:rights>by</dc:rights><dc:rights>http://creativecommons.org/licenses/by/3.0/es/</dc:rights><dc:rights>info:eu-repo/semantics/openAccess</dc:rights></dc:dc>

</collection>